Metraipolis › archive › dc_72f760245db3
Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis — Europe PMC PMID:41820200
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41820200
- DOI
- 10.1080/07853890.2026.2641930
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T04:36:19.414Z
- SHA-256 of the archived text
fbf0b0c9794f6e8b4e87bdc2cb9f01ad51e35082e55e97221feace1cf154fecd- Stable URL of this page
https://metraipolis.com/documento/dc_72f760245db3
How to cite
Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis — Europe PMC PMID:41820200 — Europe PMC (en), https://europepmc.org/article/MED/41820200 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72f760245db3 (Metraipolis archive dc_72f760245db3, sha256 fbf0b0c9794f6e8b4e87bdc2cb9f01ad51e35082e55e97221feace1cf154fecd)
BibTeX
@misc{dc72f760245db3,
title = {Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis — Europe PMC PMID:41820200},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41820200},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72f760245db3; sha256 fbf0b0c9794f6e8b4e87bdc2cb9f01ad51e35082e55e97221feace1cf154fecd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41820200. Agents can read the archived copy with the MCP tool read_document.